rs13277113 — BLK

BLK rs13277113 — The B-Cell Signaling Dimmer

BLK (B-lymphoid tyrosine kinase)¹¹ BLK (B-lymphoid tyrosine kinase)
A Src-family non-receptor tyrosine kinase expressed almost exclusively in B cells and plasmacytoid dendritic cells encodes a kinase that plays a critical role in B-cell receptor (BCR) signaling and B-cell development. Acting as an accelerator for BCR-driven activation signals, BLK helps B cells respond to antigen stimulation — but crucially, it also participates in the central tolerance checkpoint²² central tolerance checkpoint
The process by which immature B cells that recognize self-antigens are eliminated or silenced in the bone marrow before they can cause harm that eliminates self-reactive B cells. The rs13277113 SNP sits in the promoter region upstream of the BLK transcription start site: the A risk allele reduces BLK mRNA levels in B-cell lines, and carriers show lower BLK expression³³ carriers show lower BLK expression
Pamuk et al. 2017 measured BLK mRNA in blood samples of 84 SLE patients: expression was 0.52× that of controls in circulating immune cells.

The Mechanism

BLK is a Src-family kinase⁴⁴ Src-family kinase
A family of non-receptor tyrosine kinases including Src, Fyn, Lck, and Lyn. BLK is the B-cell-specific member expressed at high levels in B cells from the pre-B cell stage onward. Within the B-cell receptor signaling complex, BLK phosphorylates downstream substrates that both activate B-cell responses to antigen and help establish negative selection of self-reactive clones. When BLK expression is reduced by the A allele, this tolerance mechanism is partially impaired: B cells that recognize self-antigens escape deletion more readily. The result is a subtle shift toward B-cell hyperactivation and increased autoantibody production⁵⁵ increased autoantibody production
Including anti-dsDNA and anti-Smith antibodies characteristic of SLE, and anti-SSA/SSB antibodies in Sjögren's syndrome, the hallmark of multiple systemic autoimmune diseases.

The variant is located at chromosome 8p23.1 in the FAM167A-BLK locus. Notably, the A allele at rs13277113 is also associated with increased expression of the neighboring gene C8orf13/FAM167A⁶⁶ increased expression of the neighboring gene C8orf13/FAM167A
The risk allele reduces BLK but increases FAM167A expression; the functional consequences of elevated FAM167A remain incompletely characterized, suggesting the regulatory region affects a shared promoter element.

The Evidence

The discovery GWAS⁷⁷ discovery GWAS
Hom G et al. 2008 — 1,311 SLE cases, 1,783 North American controls; replicated in 793 Swedish cases and 857 Swedish controls published in the New England Journal of Medicine identified rs13277113 as a genome-wide significant SLE susceptibility locus (OR=1.39, P=1×10⁻¹⁰). Crucially, the study also showed that the A allele correlated with reduced BLK mRNA levels in B-cell lines, providing direct mechanistic evidence linking a regulatory variant to altered gene expression to disease risk.

Subsequent meta-analyses have firmly established this association. A 2011 meta-analysis⁸⁸ 2011 meta-analysis
Fan et al. — 11,796 SLE cases and 20,271 controls across six studies found an overall A-allele OR of 1.42 with no publication bias and no heterogeneity, supporting a highly consistent effect. The largest 2017 meta-analysis⁹⁹ 2017 meta-analysis
Song and Lee — 17 studies, 22,701 cases, 36,365 controls confirmed OR=1.36 (P<1×10⁻⁸) consistent across Caucasian, Asian, and African populations. A broader autoimmune disease meta-analysis¹⁰¹⁰ broader autoimmune disease meta-analysis
Zeng et al. 2017 — 24 studies, 31,095 cases, 39,077 controls for rs13277113 covering SLE, RA, Sjögren's, and other conditions found rs13277113 A vs G: OR=1.33 (95% CI 1.27–1.39), with the strongest associations in Asian populations.

Beyond SLE, BLK rs13277113 is associated with systemic sclerosis¹¹¹¹ systemic sclerosis
Gourh P et al. 2009: 1,050 SSc cases and 694 controls (North American) + 589 SSc cases and 722 controls (Spanish) (OR=1.32 U.S., OR=1.20 combined), particularly with the limited cutaneous and anti-centromere antibody subsets. A French cohort meta-analysis¹²¹² meta-analysis
Coustet et al. 2011 — 6,078 individuals; strongest effect in diffuse cutaneous SSc (OR=1.27) found additive effects between BLK and BANK1 in driving systemic sclerosis risk.

Clinical observations add important nuance: a Turkish cohort study found that the GA genotype¹³¹³ GA genotype
Pamuk et al. 2017 — 84 SLE patients and 105 controls was present in 48.8% of SLE patients versus 31.4% of controls (p=0.035), and SLE patients with the GA genotype had significantly more disease flares¹⁴¹⁴ disease flares
Assessed by SELENA-SLEDAI flare index: 70% of GA carriers vs 37% of non-carriers experienced flares during follow-up.

Practical Implications

Carriers of the A allele — particularly AA homozygotes — have a modestly elevated lifelong background risk for B-cell-driven autoimmune diseases. The most important practical steps are recognizing the early warning signs and ensuring prompt diagnosis if symptoms emerge. The diseases associated with BLK variants — SLE, Sjögren's syndrome, and systemic sclerosis — are all manageable with modern treatments¹⁵¹⁵ manageable with modern treatments
Including hydroxychloroquine, low-dose corticosteroids, biologics (belimumab, rituximab), and immunomodulatory drugs when caught early, but can cause significant organ damage if untreated.

The genetic risk from rs13277113 is modest in absolute terms — most carriers will not develop autoimmune disease. However, it meaningfully shifts the probability calculation and warrants increased vigilance: unexplained joint pain, persistent fatigue, rashes (especially malar/butterfly rash), Raynaud's phenomenon, persistent dry eyes or mouth, and abnormal inflammatory markers all warrant autoimmune workup in risk-allele carriers.

There are no supplement or dietary interventions proven to counteract BLK-mediated B-cell dysregulation. The actions center on monitoring, early detection, and avoiding immune-modulating triggers where possible.

Interactions

The most clinically relevant epistatic interaction is with BANK1 rs10516487¹⁶¹⁶ BANK1 rs10516487
BANK1 R61H, a missense variant in a B-cell scaffold protein that promotes BCR hyperactivation. In a Mexican Latin-American cohort, individuals carrying risk alleles at both BLK rs13277113 and BANK1 rs10516487 showed an interaction OR of 2.36 (P<0.0001) for primary Sjögren's syndrome — substantially higher than either variant alone. An independent trans-ethnic meta-analysis¹⁷¹⁷ trans-ethnic meta-analysis
Génin et al. 2013 — 1,915 RA cases and 1,915 controls from France, Spain, and Japan found a gene-gene interaction between BLK rs13277113 and BANK1 rs3733197 in rheumatoid arthritis (P=0.037): in individuals with BLK GG genotype, the BANK1 G allele increased RA risk (OR=1.21). Both BLK and BANK1 converge on B-cell receptor signaling; their co-occurrence appears to push B-cell hyperactivation beyond what either variant achieves alone.

BLK risk alleles also show partial overlap¹⁸¹⁸ partial overlap
Both PTPN22 R620W and BLK rs13277113 independently predispose to SLE and RA through distinct B-cell and T-cell tolerance mechanisms with PTPN22 rs2476601 (R620W) in autoimmune disease architecture, though BLK specifically affects B-cell tolerance while PTPN22 affects both B-cell and T-cell receptor signaling thresholds.